Abstract:OBJECTIVES: Cell-free DNA based non-invasive prenatal testing (NIPT) has been shown with closeto-diagnosis sensitivity and specificity in detecting fetal T21, T18, and T13. Future development of this technology focuses on detection of other chromosomal aneuploidies, and more importantly chromosome copy number variants (CNVs) and single-gene mutations. Validation studies were carried out to demonstrate the feasibility of detecting CNVs and single-gene disease by exploiting the cell-free DNA testing strategy and existing NIPT platforms. METHOD: For testing CNVs, 35 plasma samples with known fetal CNVs (>10 Mb in size) were recruited, together with 1077 plasma samples with normal fetal karyotypes as the control. The samples were blindly tested using the routine NIPT testing pipelines adopted at the clinical laboratories of BGI, and analyzed with the proprietary FCAPS protocol. Results were compared to the karyotyping results to calculate the sensitivity and specificity of the NIPT test. For testing single-gene disease, we developed a unique haplotype-assisted approach which was validated in a Maple Syrup Urine Disease (MSUD) case. In a trio family (father, mother in early pregnancy, and proband), targeted sequencing (180X) of the known genes causing MSUD was used to identify the disease causative mutations in the proband child and parents. At 13 gestational weeks, maternal plasma DNA and genomic DNA of the trio family were tested with a customized array at the sequencing depth of 40X and 20X respectively to retrieve the SNPs information for the purpose of parental haplotypes deduction. Linkage analysis and Hidden Markov Model were then used to construct the fetal genotype and haplotype flanking the MSUD mutation region. RESULTS: For CNV detection, with on average 4–5 M reads per sample and the existing NIPT platforms, we were able to use the FCAPS analytic protocol to identify 32 positive samples in total of 35, and generated 6 false positive cases, leading to overall sensitivity and specificity of 91.4% and 99.4% respectively. False positive rate and false negative rate of the test were 0.56% and 0.28% respectively. We also showed that with an increased sequencing depth, the detection power of the test can be further improved. In the MUSD case, deep targeted sequencing in the trio family identified that the proband child carries a missense mutation and a large deletion on BCKDHA gene, which were inherited from the mother and father respectively. With the SNP markers of the proband and parents, parental haplotype of chromosome 19 in 6148 loci were recovered. After fetal haplotype construction, the same alleles as that of the proband in the causative gene BCKDHA were inherited to the fetus, indicating that the fetus is a MSUD patient. This result was later confirmed by invasive diagnosis, and led to a well-informed decision after post-test counselling. CONCLUSIONS: We demonstrate the successful application of NIPT in detection of CNVs larger than 10 Mb without changing much to the current pipelines of aneuploidy detection. It has the potential to be integrated into the current NIPT test and offer extra benefits to the clinical service. The haplotype-assisted approach we developed requires minimum genetic information to accurately predict fetal condition. It has the clinical potential for noninvasive prenatal diagnosis of single gene disease for family with a proband child and seeks a second healthy child.

Simultaneous Quantification of 11 Pivotal Metabolites in Neural Tube Defects by HPLC-electrospray Tandem Mass Spectrometry.

Simultaneous Determination of Sixteen Metabolites Related to Neural Tube Defects in Maternal Serum by Liquid Chromatography Coupling with Electrospray Tandem Mass Spectrometry.

Pathogenesis of neural tube defects: the story beyond methylation or one-carbon unit metabolism

Neural Tube Defects and Disturbed Maternal Folate- and Homocysteine-Mediated One-Carbon Metabolism

Noninvasive detection of chromosomal CNV and single gene disease by massively parallel sequencing of cfDNA

Metabonomic Study on Women of Reproductive Age Treated with Nutritional Intervention: Screening Potential Biomarkers Related to Neural Tube Defects Occurrence

Nutrition, One-Carbon Metabolism and Neural Tube Defects: A Review

Metabonomic Profiling of Human Placentas Reveals Different Metabolic Patterns among Subtypes of Neural Tube Defects

Metabolic Signature of Pregnant Women with Neural Tube Defects in Offspring.

Identification of PCSK9 As a Novel Serum Biomarker for the Prenatal Diagnosis of Neural Tube Defects Using Itraq Quantitative Proteomics

Selective Screening for Inborn Errors of Metabolism and Secondary Methylmalonic Aciduria in Pregnancy at High Risk District of Neural Tube Defects: a Human Metabolome Study by GC-MS in China.

Quantitative assessment of maternal biomarkers related to one-carbon metabolism and neural tube defects

High Ratios Of C20:4n-6/C20:5n-3 And Thromboxane B-2/6-Keto-Prostaglandin F-1 Alpha In Placenta Are Potential Risk Contributors For Neural Tube Defects: A Case-Control Study In Shanxi Province, China

A Comparative Study among Folic Acid and Its Related Metabolites on Risk Assessment and Prediction of Neural Tube Defects

Simultaneous quantification of 26 NAD-related metabolites in plasma, blood, and liver tissue using UHPLC-MS/MS

Multiplexing of TMT labeling reveals folate-deficient diet-specific proteome changes in NTDs

High Ratios of C20:4n-6/C20:5n-3 and Thromboxane B2 /6-Keto-prostaglandin F1α in Placenta Are Potential Risk Contributors for Neural Tube Defects: A Case-Control Study in Shanxi Province, China.

Complement factors and alpha‐fetoprotein as biomarkers for noninvasive prenatal diagnosis of neural tube defects

Association of Neural Tube Defects with Maternal Alterations and Genetic Polymorphisms in One-Carbon Metabolic Pathway

Relation Between Hypomethylation of Long Interspersed Nucleotide Elements and Risk of Neural Tube Defects

Noninvasive fetal genotyping of single nucleotide variants and linkage analysis for prenatal diagnosis of monogenic disorders